Sato Shigeki, Nagai Hideaki
Department of Medical Oncology and Immunology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya-shi, Aichi 467-8601 Japan.
Kekkaku. 2011 Feb;86(2):101-12.
QuantiFERON TB-2G (QFT) is widely used in clinical settings for the identification of tuberculosis infection because of its high level of utility. It is well known that QFT stimulates peripheral blood lymphocytes in vitro by means of M. tuberculosis-specific protein, and that infection is identified by measuring the interferon-gamma released. Interpretation of QFT results is therefore difficult in immunosuppressed subjects in whom the function of immunocompetent cells, including lymphocytes, is suppressed, making it difficult for them to produce interferon-gamma. There is a high incidence of tuberculosis among hemodialysis patients. It has been conjectured that the use of powerful immunosuppressive agents following kidney transplantation results in a high risk of tuberculosis. How QFT results change immediately following kidney transplantation is an extremely interesting question. In recent years, an increasing number of institutions have been using TNF-alpha inhibitors to treat rheumatoid arthritis patients. Is QTF useful for identifying whether patients have latent tuberculosis infection before the administration of anti-TNF antibodies? In particular, many rheumatoid arthritis patients may have been given methotrexate or glucocorticoids, which suppress the immune system, prior to the administration of TNF-alpha inhibitors, possibly making it difficult to interpret the QFT results. We must be aware of this limitation when performing QFT on immunosuppressed patients. It is also important that we understand the clinical parameters influencing QFT results (such as lymphocyte counts). The morbidity rate of tuberculosis is high among healthcare workers, particularly nurses. A number of studies have reported that QFT is useful in hospital infection control for tuberculosis, but the effectiveness of QFT for monitoring the health of healthcare workers is still not fully understood. In this symposium, we will debate how far QFT can be used and the extent of its usefulness under exceptional circumstances. (1) How do we manage kidney transplant recipients with latent tuberculosis infection?: Norihiko GOTO (Transplant Surgery, Nagoya Daini Red Cross Hospital) It is unclear whether QuantiFERON-second generation (QFT-2G) is useful for diagnostic screening and follow up of latent tuberculosis infection (LTBI) in immunosuppressed kidney transplant (KTx) recipients. The QFT-2G assay that included response to mitogen stimulation was performed before and 6 months after KTx. Non responder was 0 (0%) at baseline, 3 (3%) at 6 months. Response to mitogen stimulation was 9.7 +/- 5.3 IU/mL at baseline vs. 10.4 +/- 5.0 IU/mL at 6 months after KTx (p = 0.29). QFT-2G is a useful screening test for LTBI and active tuberculosis (TB) even during maintenance of immunosuppression of KTx. (2) QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients for assessing latent tuberculosis infection prior treatment of anti-tumor necrosis factor antibody: Shogo BANNO (Division of Rheumatology and Nephrology, Department of Internal Medicine, Aichi Medical School of Medicine) To determine the positive rate of LTBI in RA patients using the QFT-2G test, we divided RA patients into two groups: with or without old TB findings by chest CT. With a cutoff level set at 0.35 IU/ml, the positive rate of QFT-2G in LTBI was detected only 5.8%, when setting cutoff at 0.1 IU/ml (lower cutoff level), 23.1% was detected in LTBI patients. The positive TST results were significantly increased in non-LTBI patients compared than in LTBI patients. The QFT-2G test was not affected by the treatment of MTX, and the incidence of indeterminate result was low. The QFT-2G was useful compared to TST before administration of TNF inhibitors in RA patients, because of superior specificity of QFT-2G. (3) Clinical parameters that influence the sensitivity of T-cell assays: Haruyuki ARIGA (National Hospital Organization Tokyo National Hospital) The detection of tuberculosis (TB) infection in compromised hosts is essential for TB control, but T cell assay might be influenced by the degree of cell-mediated immunosuppression. The relationship between immunocompetence and specific interferon (IFN)-gamma response in whole blood QuantiFERON-TB Gold (QFT) is uncertain. Immune-related clinical indicators associated with the degree of antigen-specific IFN-gamma production were analysed using a large immunologically-unselected population with obvious TB infection. The absolute number of blood lymphocyte in TB patients was significantly associated with specific IFN-gamma production in a linear regression model. Sensitivity of 2 IFN-gamma Release Assays, QFT and ELISPOT, partly depends on peripheral lymphocyte counts. At low lymphocyte count conditions, ELISPOT assay is superior to whole blood QFT for detecting tuberculosis infection. (4) QuantiFERON TB-2G among staffs in the hospitals of Nationao Hospital Organization: Susumu OGURI, Chihiro NISHIO, Kensuke SUMI, Masayoshi MINAGUCHI, Tomomasa TSUBOI, Atuo SATOU, Osamu TOKUNAGA, Takeshi MIYAMOMAE, Takuya KURASAWA (National Hospital Organization Minami-Kyoto National Hospital)
To investigate the infection rate of tuberculosis among staffs working in the hospitals of NHO.
Questionnaires were sent to the hospitals and the responses were analyzed.
Among the staffs working in the hospitals with tuberculosis wards, positive rate of QuantiFERON TB-2G was 6.9%, probable positive rate was 5.6%. On the other hand, among the staffs working in the hospitals without tuberculosis wards, positive rate was 4.4%, probable positive rate was 3.9%.
It is necessary to monitor the infection rate among hospital staffs.
QuantiFERON TB-2G(QFT)因其高度实用性在临床环境中被广泛用于结核病感染的识别。众所周知,QFT通过结核分枝杆菌特异性蛋白在体外刺激外周血淋巴细胞,并通过测量释放的干扰素-γ来识别感染。因此,在免疫抑制患者中,由于包括淋巴细胞在内的免疫活性细胞功能受到抑制,难以产生干扰素-γ,QFT结果的解读较为困难。血液透析患者中结核病发病率较高。据推测,肾移植后使用强效免疫抑制剂会导致结核病的高风险。肾移植后QFT结果如何立即变化是一个极其有趣的问题。近年来,越来越多的机构使用肿瘤坏死因子-α抑制剂治疗类风湿关节炎患者。在给予抗TNF抗体之前,QTF对于识别患者是否存在潜伏性结核感染是否有用?特别是,许多类风湿关节炎患者在给予TNF-α抑制剂之前可能已经接受了抑制免疫系统的甲氨蝶呤或糖皮质激素治疗,这可能导致难以解读QFT结果。在对免疫抑制患者进行QFT检测时,我们必须意识到这一局限性。了解影响QFT结果的临床参数(如淋巴细胞计数)也很重要。医护人员,尤其是护士中结核病的发病率较高。多项研究报告称,QFT在医院结核病感染控制中有用,但QFT对医护人员健康监测的有效性仍未完全了解。在本次研讨会上,我们将讨论QFT在多大程度上可以使用以及在特殊情况下其有用性的程度。(1)如何管理潜伏性结核感染的肾移植受者?:后藤典彦(名古屋第二红十字医院移植外科)尚不清楚第二代QuantiFERON(QFT-2G)是否可用于免疫抑制肾移植(KTx)受者潜伏性结核感染(LTBI)的诊断筛查和随访。在KTx前和KTx后6个月进行了包括对有丝分裂原刺激反应的QFT-2G检测。基线时无反应者为0(0%),6个月时为3(3%)。KTx后6个月对有丝分裂原刺激的反应在基线时为9.7±5.3 IU/mL,而在KTx后6个月为10.4±5.0 IU/mL(p = 0.29)。即使在KTx免疫抑制维持期间,QFT-2G也是LTBI和活动性结核病(TB)的有用筛查试验。(2)日本类风湿关节炎患者中用于评估抗肿瘤坏死因子抗体治疗前潜伏性结核感染的QuantiFERON-TB Gold:番野翔吾(爱知医科大学内科风湿病与肾脏病科)为了使用QFT-2G检测确定类风湿关节炎患者中LTBI的阳性率,我们将类风湿关节炎患者分为两组:胸部CT有无陈旧性结核表现。将临界值设定为0.35 IU/ml时,LTBI中QFT-2G的阳性率仅为5.8%,当将临界值设定为0.1 IU/ml(较低临界值)时,LTBI患者中检测到23.1%。非LTBI患者的阳性结核菌素试验结果比LTBI患者显著增加。QFT-2G检测不受甲氨蝶呤治疗的影响,不确定结果的发生率较低。在类风湿关节炎患者中,在给予TNF抑制剂之前,QFT-2G与结核菌素试验相比更有用因为QFT-2G具有更高的特异性。(3)影响T细胞检测敏感性的临床参数:有贺春之(国立医院组织东京国立医院)在免疫功能受损宿主中检测结核(TB)感染对于结核病控制至关重要,但T细胞检测可能会受到细胞介导免疫抑制程度的影响。全血QuantiFERON-TB Gold(QFT)中免疫能力与特异性干扰素(IFN)-γ反应之间的关系尚不确定。使用大量未经免疫选择且有明显结核感染的人群分析了与抗原特异性IFN-γ产生程度相关的免疫相关临床指标。在一个线性回归模型中,结核病患者血液淋巴细胞的绝对数量与特异性IFN-γ产生显著相关。两种IFN-γ释放检测方法QFT和ELISPOT)的敏感性部分取决于外周淋巴细胞计数。在淋巴细胞计数较低时,ELISPOT检测在检测结核感染方面优于全血QFT。(4)国立医院组织医院工作人员中的QuantiFERON TB-2G:小栗进、西尾千寻、三见健介、皆口正义、津井友政、佐藤敦夫、德永修、宫间武史、仓泽拓也(国立医院组织南京都医院)
调查国立医院组织医院工作人员中的结核感染率。
向各医院发送问卷并分析回复。
在设有结核病病房的医院工作人员中,QuantiFERON TB-2G的阳性率为6.9%,可能阳性率为5.6%。另一方面,在没有结核病病房的医院工作人员中,阳性率为4.4%,可能阳性率为3.9%。
有必要监测医院工作人员中的感染率。